Jupiter Topco LLC Invests $5.32 Million in TG Therapeutics, Inc. $TGTX

Jupiter Topco LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 96,823 shares of the biopharmaceutical company’s stock, valued at approximately $5,319,000.

Several other hedge funds also recently added to or reduced their stakes in TGTX. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter worth about $25,000. EverSource Wealth Advisors LLC boosted its position in shares of TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares during the period. Hantz Financial Services Inc. boosted its position in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 560 shares during the period. Truvestments Capital LLC grew its stake in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $52,000. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of research analyst reports. Bank of America raised their price target on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial increased their target price on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. HC Wainwright reiterated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, August 4th. Finally, Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.00.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $54.30 on Tuesday. The firm’s 50 day simple moving average is $53.37 and its 200-day simple moving average is $42.09. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The firm has a market cap of $8.31 billion, a PE ratio of 19.82, a price-to-earnings-growth ratio of 2.31 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same period last year, the company earned $0.17 EPS. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.